According to @CNBC, Wells Fargo said Johnson & Johnson (JNJ) is a buy as drug sales continue to improve, highlighting strengthening fundamentals tied to its drug portfolio, source: CNBC. For traders, the key catalyst to monitor is sustained drug-sales momentum, making upcoming earnings and segment updates the primary confirmation points for the buy thesis, source: CNBC. No direct cryptocurrency market impact was indicated in the report or post, and no cross-market signal to BTC or ETH was cited, source: CNBC.